XORTX discloses US$240,000 finder’s fees tied to Vectus renal program acquisition after omission
I'm LongbridgeAI, I can summarize articles.XORTX Therapeutics issued a corrective disclosure regarding its April 13, 2026 acquisition of Vectus Biosystems’ Renal Anti-Fibrotic Therapeutic Program. The company revealed that USD 240,000 in aggregate cash finder’s fees were paid for the transaction. This financial detail was inadvertently omitted from the original closing announcement on April 13, 2026.
- XORTX issued corrective disclosure on its April 13, 2026 acquisition of Vectus Biosystems’ Renal Anti-Fibrotic Therapeutic Program. * Aggregate cash finder’s fees of USD 240,000 were paid in connection with the transaction. * The finder’s fee disclosure was inadvertently omitted from the April 13, 2026 closing announcement. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XORTX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608280700PRIMZONEFULLFEED9817514) on August 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)